| P2093 | author name string | T Lebret | |
| | A Méjean | |
| P2860 | cites work | Combination chemotherapy for advanced bilharzial bladder carcinoma | Q71751996 |
| | Carboplatin-based chemotherapy for bladder cancer | Q72559643 |
| | Urachal cancer: role of conservative surgery | Q72645719 |
| | Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy | Q73042239 |
| | Malignant pheochromocytoma of the bladder: current controversies | Q73071815 |
| | Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma | Q73181726 |
| | Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract | Q73445663 |
| | Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 |
| | Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer | Q73719687 |
| | Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma | Q73872746 |
| | Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European | Q73881573 |
| | Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years | Q74237326 |
| | Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases | Q74468482 |
| | Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma | Q74545986 |
| | Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success | Q74804633 |
| | Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study | Q77435874 |
| | Bladder cancer | Q77503970 |
| | Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium | Q79329951 |
| | Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium | Q79899307 |
| | Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients | Q80493136 |
| | Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer | Q80785289 |
| | Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder | Q81441276 |
| | Cystectomy for carcinoma of the bilharzial bladder. 126 patients 10 years later | Q93569671 |
| | Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium | Q93606365 |
| | Cancer statistics, 2008 | Q27860585 |
| | Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 |
| | Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 |
| | Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | Q33331273 |
| | Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function | Q33333141 |
| | Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. | Q33334087 |
| | Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study | Q33335472 |
| | Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer | Q33337149 |
| | Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network | Q33337751 |
| | Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. | Q33340282 |
| | Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer | Q33341273 |
| | Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group | Q33357994 |
| | Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study | Q33365072 |
| | Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). | Q33369889 |
| | A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract | Q33370794 |
| | Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium | Q33371986 |
| | A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. | Q33372087 |
| | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study | Q33374499 |
| | Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 |
| | Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 |
| | Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 |
| | Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 |
| | Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen | Q33501448 |
| | Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience | Q34182866 |
| | Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases | Q34537230 |
| | Current and future perspectives in advanced bladder cancer: is there a new standard? | Q34563646 |
| | Novel gemcitabine-containing triplets in the management of urothelial cancer | Q34563657 |
| | Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer | Q34563669 |
| | Future directions for gemcitabine in the treatment of genitourinary cancer | Q34563674 |
| | High-risk metastatic urothelial cancer: chances for cure? | Q34781373 |
| | New drugs and new approaches for the treatment of metastatic urothelial cancer | Q34798504 |
| | A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract | Q46565121 |
| | Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later | Q46599382 |
| | Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 |
| | Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience | Q46737967 |
| | Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. | Q53263269 |
| | Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. | Q53584625 |
| | Advanced carcinoma of bladder: treatment using hypogastric artery infusion with 5-fluorouracil, either as a single agent or in combination with bleomycin or adriamycin and supervoltage radiation. | Q54264642 |
| | Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. | Q54418734 |
| | Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group | Q57905078 |
| | Adjuvant chemotherapy in muscle-invasive bladder carcinoma | Q61899595 |
| | [Urothelial tumors] | Q63966484 |
| | Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update | Q67934383 |
| | Advanced small cell carcinoma of the bladder. Successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy | Q68468559 |
| | A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 |
| | Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer | Q68891233 |
| | Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder | Q68967650 |
| | Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia | Q69049480 |
| | Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C | Q69962359 |
| | Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy | Q70113435 |
| | Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors | Q70395690 |
| | Intravesical cisplatin for superficial bladder tumors | Q70678275 |
| | Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center | Q71238240 |
| | Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy | Q71667709 |
| | Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? | Q34981080 |
| | The role of systemic chemotherapy in the management of muscle-invasive bladder cancer | Q35021331 |
| | Gemcitabine in transitional cell carcinoma of the urothelium | Q35070414 |
| | Review of a promising new agent--pemetrexed disodium | Q35097974 |
| | Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium | Q35592216 |
| | Focus on bladder cancer | Q35868630 |
| | A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B | Q36115630 |
| | Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 |
| | Update on chemotherapy for advanced bladder cancer | Q36157935 |
| | Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review | Q36168816 |
| | Systemic chemotherapy in inoperable or metastatic bladder cancer | Q36320015 |
| | Developing innovative strategies for advanced transitional cell carcinoma of the bladder | Q36352085 |
| | From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates | Q36354734 |
| | A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen | Q36614243 |
| | Systemic chemotherapy for advanced bladder cancer: update and controversies | Q36678648 |
| | Urachal carcinoma: surgical and chemotherapeutic options | Q36689127 |
| | Muscle-invasive urothelial carcinoma of the bladder | Q36729131 |
| | Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. | Q36729145 |
| | Biology and management of bladder cancer | Q37911018 |
| | Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients | Q39217891 |
| | Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature | Q39616770 |
| | Methotrexate: an active drug in bladder cancer | Q40279428 |
| | Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group | Q40558439 |
| | Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial | Q40680796 |
| | Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial | Q40704537 |
| | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 |
| | Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel | Q41144344 |
| | Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point | Q41747152 |
| | Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 |
| | Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy | Q43564933 |
| | Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin | Q43666929 |
| | A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer | Q43777231 |
| | Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. | Q43801249 |
| | Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer | Q43899651 |
| | Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma | Q44044786 |
| | Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer | Q44243828 |
| | Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy | Q44578641 |
| | A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma | Q44635857 |
| | Malignant pheochromocytoma of the urinary bladder: effectiveness of radiotherapy in conjunction with chemotherapy | Q44792083 |
| | A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer | Q45090161 |
| | Gemcitabine and cisplatin following surgical treatment of urinary bladder carcinosarcoma. | Q45228507 |
| | Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer | Q45262851 |
| | Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. | Q45967681 |
| | A nonplatinum combination in metastatic transitional cell carcinoma | Q46415342 |
| P407 | language of work or name | French | Q150 |
| P304 | page(s) | S261-76 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie | Q27710086 |
| P1476 | title | Metastases from urethelial carcinoma: role of chemotherapy | |
| P478 | volume | 18 Suppl 7 | |